IFRX:NSD-InflaRx N.V. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.28

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.21M

Analyst Target

USD 9.28
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+8.54 (+1.70%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

+2.52 (+0.38%)

USD 76.39B
ARGX argenx NV ADR

-7.07 (-1.15%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

+7.36 (+2.60%)

USD 31.94B
ONC BeiGene, Ltd.

+1.22 (+0.48%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.05 (+0.15%)

USD 19.31B
SMMT Summit Therapeutics PLC

+0.94 (+4.76%)

USD 14.57B
UTHR United Therapeutics Corporatio..

+6.87 (+2.19%)

USD 14.37B
INCY Incyte Corporation

+0.86 (+1.39%)

USD 14.22B
MRNA Moderna Inc

+1.51 (+4.62%)

USD 13.74B

ETFs Containing IFRX

NRGY:CA Global X Equal Weight Can.. 9.37 % 0.00 %

+0.25 (+1.23%)

CAD 0.21B
ZEO:CA BMO Equal Weight Oil & Ga.. 9.31 % 0.61 %

+0.87 (+1.23%)

CAD 0.20B
XEG:CA iShares S&P/TSX Capped En.. 5.82 % 0.61 %

+0.26 (+1.23%)

CAD 1.56B
ENCC:CA Global X Canadian Oil and.. 5.54 % 0.00 %

+0.10 (+1.23%)

CAD 0.50B
PWER Macquarie ETF Trust 4.00 % 0.00 %

+0.35 (+1.23%)

USD 6.54M
XMD:CA iShares S&P/TSX Completio.. 2.34 % 0.61 %

+0.40 (+1.23%)

CAD 0.27B
ENY 0.00 % 0.66 %

N/A

N/A
FQC:CA 0.00 % 1.01 %

N/A

N/A
HEE:CA 0.00 % 0.84 %

N/A

N/A
SCHC Schwab International Smal.. 0.00 % 0.12 %

+0.06 (+1.23%)

N/A
ZJO:CA 0.00 % 0.60 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.18% 14% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.18% 14% F 8% B-
Trailing 12 Months  
Capital Gain -14.09% 69% C- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.09% 69% C- 40% F
Trailing 5 Years  
Capital Gain -62.90% 50% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.90% 50% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -6.87% 41% F 26% F
Dividend Return -6.87% 41% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 72.84% 48% F 28% F
Risk Adjusted Return -9.43% 43% F 29% F
Market Capitalization 0.08B 45% F 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.